As companies and countries pour money into the effort to develop COVID-19 vaccines, timelines keep getting more ambitious and dates for delivering a workable immunization against the virus keep moving up.
Yet even with companies such as Moderna Therapeutics Inc. and AstraZeneca Plc signaling rapid progress and already enrolling patients in mid-stage trials, it would be quite a feat if we had a stockpile of proven doses by year's end. That’s a best-case scenario. A longer wait is more likely, and that may seem discouraging. The good news is, there is a batch of treatments in development with a chance of accelerated approval, and they can provide needed relief in the interim.
Dozens of approaches could serve as a valuable bridge, from repurposed drugs to bespoke antibody cocktails. None can replace the value of a vaccine in getting the world back to normal, but the availability of more treatment options for sick patients could help to increase the chances of a faster and fuller recovery, and reduce the lethality of the disease. Two of the most familiar treatments options — the malaria drug hydroxychloroquine and Gilead Sciences Inc.’s remdesivir — have recently run into issues over safety and degree of efficacy, but there are plenty more in the pipeline.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.